Active ingredientCarteolol HClCat. No. P-C061-001CAS 51781-21-6Family · Pharmaceutical analytical standards
Carteolol
A non-selective beta blocker patented in 1972 and in use since 1980, given mainly as eye drops to lower the pressure inside the eye in glaucoma and ocular hypertension. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.
Did you know?The suffix -olol unites the beta blockers; carteolol also has mild intrinsic sympathomimetic activity, meaning it weakly stimulates the same receptors it blocks.
Go to the active ingredient →Active ingredientCarteolol HClCat. No. P-C061-001CAS 51781-21-6
Pharmacopoeial impurityCarteolol EP Impurity ICat. No. P-C061-002CAS 2748462-62-4
Pharmacopoeial impurityCarteolol HCl EP Impurity BCat. No. P-C061-003CAS 30389-33-4
Pharmacopoeial impurityCarteolol HCl EP Impurity CCat. No. P-C061-004CAS 51781-14-7
Pharmacopoeial impurityCarteolol HCl EP Impurity DCat. No. P-C061-005CAS 51781-13-6
Pharmacopoeial impurityCarteolol HCl EP Impurity ECat. No. P-C061-006CAS 56660-90-3
Pharmacopoeial impurityCarteolol HCl EP Impurity FCat. No. P-C061-007
Pharmacopoeial impurityCarteolol HCl EP Impurity GCat. No. P-C061-008CAS 54945-72-1
Pharmacopoeial impurityCarteolol Hydrochloride EP Impurity ACat. No. P-C061-009CAS 5057-12-5
Pharmacopoeial impurityCarteolol Hydrochloride EP Impurity H HydrochlorideCat. No. P-C061-010CAS 53371-79-2
Isotopically labelledCarteolol-d9 HClCat. No. P-C061-011CAS 1346602-13-8
Isotopically labelledN-Nitroso Carteolol-d9Cat. No. P-C061-012
NitrosamineN-Nitroso CarteololCat. No. P-C061-013
NitrosamineN-Nitroso Carteolol HCl EP Impurity HCat. No. P-C061-014
ImpurityCarteolol Impurity 1Cat. No. P-C061-015CAS 73098-37-0
ImpurityCarteolol Impurity 2Cat. No. P-C061-017No product matches your search.
EDQM standards 1
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.